
Quarterly report 2025-Q3
added 11-05-2025
Viemed Healthcare EBITDA 2011-2026 | VMD
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Viemed Healthcare
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.2 M | 23.9 M | 22.9 M | 25.3 M | 9.89 M | 17.6 M | 14.4 M | 5.09 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 36.2 M | 5.09 M | 19.4 M |
Quarterly EBITDA Viemed Healthcare
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.04 M | 5.45 M | 10.5 M | - | 5.98 M | 3.99 M | 8.49 M | - | 4.62 M | 3.2 M | 6.7 M | - | 12.7 M | 1 M | 5.64 M | - | 11.1 M | 2.66 M | 3.94 M | 5.27 M | 10.8 M | 17.2 M | 6.74 M | 2.69 M | 6.58 M | 4.4 M | 3.72 M | 2.92 M | 5.12 M | 3.92 M | 2.34 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.2 M | 1 M | 6.06 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aziyo Biologics
AZYO
|
-26.8 M | - | 1.37 % | $ 20.5 M | ||
|
Bruker Corporation
BRKR
|
437 M | $ 38.77 | -1.27 % | $ 5.78 K | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-3.98 M | - | - | $ 1.77 B | ||
|
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-9.8 M | - | -5.86 % | $ 30.6 M | ||
|
Acutus Medical
AFIB
|
-11.5 M | - | -26.83 % | $ 2.62 M | ||
|
Dynatronics Corporation
DYNT
|
-1.97 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | ||
|
Cognyte Software Ltd.
CGNT
|
8.53 M | $ 8.09 | 3.45 % | $ 581 M | ||
|
Allied Healthcare Products
AHPI
|
-815 K | - | 3.58 % | $ 2.21 M | ||
|
Second Sight Medical Products
EYES
|
-24.3 M | - | -0.97 % | $ 54.4 M | ||
|
EDAP TMS S.A.
EDAP
|
-18 M | $ 4.1 | 2.76 % | $ 153 M | ||
|
Electromed
ELMD
|
10.7 M | $ 24.5 | 2.17 % | $ 207 M | ||
|
AdaptHealth Corp.
AHCO
|
473 M | $ 9.69 | 3.09 % | $ 1.31 B | ||
|
FONAR Corporation
FONR
|
9.84 M | $ 18.54 | 0.19 % | $ 122 M | ||
|
Apollo Endosurgery
APEN
|
-30.2 M | - | - | $ 475 M | ||
|
CONMED Corporation
CNMD
|
120 M | $ 42.93 | -1.11 % | $ 1.33 B | ||
|
CryoLife, Inc.
CRY
|
23.2 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
AxoGen
AXGN
|
-1.19 M | $ 29.44 | -1.31 % | $ 1.36 B | ||
|
Apyx Medical Corporation
APYX
|
-16.6 M | $ 3.26 | 2.84 % | $ 113 M | ||
|
InMode Ltd.
INMD
|
86.1 M | $ 13.55 | -0.37 % | $ 876 M | ||
|
Axonics Modulation Technologies
AXNX
|
-53.2 M | - | - | $ 3.31 B | ||
|
IRadimed Corporation
IRMD
|
22.8 M | $ 105.35 | 1.02 % | $ 1.33 B | ||
|
Soliton, Inc.
SOLY
|
-14.1 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
88.4 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-8.53 M | - | 0.03 % | $ 1.58 B | ||
|
Accuray Incorporated
ARAY
|
14 M | $ 0.52 | -0.36 % | $ 53.4 M | ||
|
Misonix, Inc.
MSON
|
-15.9 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M | ||
|
LivaNova PLC
LIVN
|
228 M | $ 66.26 | -3.17 % | $ 3.61 B | ||
|
Medigus Ltd.
MDGS
|
-9.9 M | - | 10.28 % | $ 55.5 M | ||
|
Pulmonx Corporation
LUNG
|
-56.6 M | $ 1.47 | -3.92 % | $ 57.5 M | ||
|
Cytosorbents Corporation
CTSO
|
-15.2 M | $ 0.79 | -1.75 % | $ 43 M | ||
|
Medtronic PLC
MDT
|
8.82 B | $ 96.0 | -0.75 % | $ 123 B | ||
|
Align Technology
ALGN
|
753 M | $ 181.73 | -0.5 % | $ 13.6 B | ||
|
Intersect ENT, Inc.
XENT
|
-64.8 M | - | - | $ 955 M | ||
|
Inari Medical
NARI
|
-23.4 M | - | - | $ 4.23 B | ||
|
Butterfly Network
BFLY
|
-65.5 M | $ 3.97 | 7.88 % | $ 840 M | ||
|
BIOLASE
BIOL
|
-15.1 M | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
9.49 B | $ 113.65 | 0.04 % | $ 198 B | ||
|
NuVasive
NUVA
|
147 M | - | - | $ 2.07 B | ||
|
Nevro Corp.
NVRO
|
-118 M | - | - | $ 217 M | ||
|
BioSig Technologies
BSGM
|
-12.7 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
4.98 B | $ 72.77 | -1.46 % | $ 108 B | ||
|
Orthofix Medical
OFIX
|
-4.11 M | $ 12.98 | -0.42 % | $ 514 M |